Kyverna Therapeutics Inc. Strengthens Board With The Addition Of Sravan K. Emany And Andrew Miller, Ph.D., Marking A Key Transition In Its Autoimmune CAR T Growth Strategy

Kyverna Therapeutics Inc., a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, has announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D., to its Board of Directors. As part of this leadership transition, Mr. Emany will take over as Chair of the Audit Committee, succeeding Dan Spiegelman, who has stepped down from the Board.

Chief Executive Officer Warner Biddle said the additions to the Board come at an important time for the company. He noted that Mr. Emany brings decades of strategic and financial experience, particularly in building and scaling rare disease cell and gene therapy companies for commercial readiness. He also emphasized Dr. Miller’s strong background as a research and operational leader across all stages of company growth. Both leaders are expected to play key roles as Kyverna advances its autoimmune CAR T programs and prepares for long-term growth.

Executive Chair Christi Shaw added that the new appointments enhance the Board’s depth in areas such as capital strategy, clinical development, and operations—capabilities the company sees as important for its next stage of development. She also expressed appreciation for Dan Spiegelman’s contributions during the company’s early years.

Mr. Emany currently serves as Chief Financial Officer of Beam Therapeutics. Before joining Beam, he held senior leadership roles including CFO and Chief Operating Officer at Ironwood Pharmaceuticals and Corporate Vice President and Chief Strategy Officer at Integra LifeSciences Holdings Corporation. His earlier career included a long tenure in investment banking with Bank of America and its investment banking division, BofA Securities, where he served as Managing Director in the mergers and acquisitions group. He also held positions at Goldman Sachs Group and Morgan Stanley. He is currently on the Board of Directors at Assertio Holdings Inc.. Mr. Emany earned both an M.A. and B.A. in International Relations from Johns Hopkins University and its School of Advanced International Studies.

Dr. Miller joins the Board as a well-recognized biopharmaceutical executive with expertise in R&D and corporate strategy. He was recently named to Time Magazine’s list of 100 Next Generation Leaders and 100 Most Influential People in Healthcare for 2025. Dr. Miller was the Founder and President of R&D at Karuna Therapeutics prior to its $14B acquisition by Bristol Myers Squibb in 2024. He is the lead inventor of KarXT, now marketed as COBENFY for schizophrenia, and has previously served as COO, CEO, and a member of Karuna’s Board.

Dr. Miller currently serves as Chairman of the Board at Progentos Therapeutics and as an advisor to Google Ventures, General Atlantic, Vida Ventures, Longwood Fund, and the One Mind Foundation. He holds a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from the University of Illinois at Urbana-Champaign.